Drs. J. Bennett and K. Uyhazi | University of Pennsylvania

Gene Therapy Approach with Retinal Pigmented Epithelium


Research Summary

Drs. Jean Bennett and Katherine Uyhazi Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania

November 2020 | $150,000

In the fall of 2020, Conquering Gyrate Atrophy awarded $100,000 to the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania to support research towards developing gene therapy to slow and/or reverse the progression of gyrate atrophy. The research will test the possibility of halting or reversing disease progression through a one-time delivery of the correct copy of the human OAT gene to the retinal pigmented epithelium (RPE) in animal models.

In August 2021, Conquering Gyrate Atrophy awarded a grant of $50,000 for additional support for this research. On December 8, 2021, Drs. Jean Bennett and Katherine Uyhazi spoke to the gyrate atrophy community about their research on gyrate atrophy and the research trends they are seeing for inherited retinal diseases. You can watch the full recording below.

In February 2023, Conquering Gyrate Atrophy awarded a grant of $50,000 for additional support for this research.

Results

Some results were shared at the 2024 ARVO conference. Conclusions are below and see the full abstact here.

GA-iPSCs have decreased viability upon orthinine exposure compared to wildtype iPSCs, which is robustly rescued by delivery of AAV2-hOAT. Together, these data provide pre-clinical evidence for the efficacy of gene replacement therapy in an in vitro model of gyrate atrophy and support future investigations of GA-iPSC derived retinal pigment epithelial cells and in vivo models of the disease.

 
 

Researcher Profiles


Dr. Bennett is a physician-scientist with expertise in molecular biology, vector development and gene therapy translational studies. She has established a true “from bench to bedside” program, and was the scientific leader of a team that translated reversal of blindness in animal models to demonstration of efficacy and safety in children and adults. This work led to the first and only approved gene therapy for inherited disease in USA and in Europe and the first approved gene therapy product targeting a retinal disease worldwide.

View full profile

 

Dr. Uyhazi received her B.S. from The College of New Jersey, summa cum laude, and her MD/PhD from Yale School of Medicine with her PhD in Cell Biology. She completed her residency in ophthalmology and her fellowship in retinal degenerations at the Scheie Eye Institute at the University of Pennsylvania.   She is currently an Assistant Professor of Ophthalmology at Penn where she has a clinical practice for inherited retinal diseases and also runs a lab focused on developing new gene therapy and stem cell therapies for retinal diseases.​

View full profile 

 

Feeling inspired by this work? Here are ways you can keep advancing our research efforts

Explore research grants.

Apply for funding and learn about current research.

Learn more

Connect to our community.

Join our patient family community to advocate for a cure for gyrate atrophy. 

Read more

Donate today.

We are a parent-led all-volunteer effort. Every contribution matters.

Give now

Erin Corradi

Brainstorming is my passion—not just brainstorming, but taking an idea, looking at the numbers, setting up tactics and timelines, and seeing that idea become a meaningful, enduring success.

From the analytical to the creative, I enjoy being involved in it all. When we work together, each contributing our strengths, we can take a good idea and make it greater; we can take an important message and make it clearer; we can take a life-changing cause and effectively do something about it. 

https://erincorradi.com
Previous
Previous

Gyrate Atrophy Scientific Symposium

Next
Next

Fabricio | Argentina